Canada’s federal health regulator received more than 1,100 responses from the public for its review of the potential market for cannabis health products, demonstrating strong industry interest in the potential new category.
Matt Lamers
Matt Lamers's Latest Posts
Licensed outdoor cannabis canopy exceeds indoor for first time in Canada
The amount of space licensed to grow cannabis in Canada is now heavily skewed toward outdoor cultivation instead of indoor for the first time, according to new data from Health Canada. The federal regulator said it has licensed roughly 13 million square feet of indoor...
Australia expedites review of medical cannabis product Epidiolex
The only medical cannabis product in the Australian Register of Therapeutic Goods might soon be joined by another.
Executive exodus continues in cannabis boardrooms with Sundial CEO’s resignation
Turnover inside the boardrooms of Canadian cannabis producers shows no sign of slowing. Cannabis producer Sundial Growers said Thursday that Torsten Kuenzlen stepped down as a director and CEO "to pursue other interests." His departure is effective immediately....
Australia to wrap up CBD review by March
Australian health authorities expect to conclude their safety review of cannabidiol in low doses in March, the results of which could inform any decision to down-schedule the popular cannabinoid. Any move to reschedule certain doses of CBD, making it available over...
Australia says over-the-counter CBD sales ‘could be considered during 2020’
A review of cannabidiol products being undertaken by Australian health authorities could result in the relaxation of the scheduling status of CBD, potentially making it available over the counter in low doses. In a public submission to a Senate committee studying...
Former Roche executive takes helm of New Zealand cannabis firm Rua Bioscience
Longtime Roche executive Rob Mitchell is taking the reins of New Zealand medical cannabis firm Rua Bioscience, replacing co-founder Manu Caddie as CEO. Mitchell spent most of his career heading global product strategy for Roche, a multinational health-care company....
New Zealand’s adult-use cannabis referendum is set for September
New Zealand has scheduled a date for its next general election, which will coincide with a referendum on the legalization of recreational cannabis. On Sept. 19, New Zealanders will be asked to answer the straightforward question, “Do you support the proposed Cannabis...
Realistic expectations for New Zealand’s cannabis market: Q&A with Rua Bioscience CEO Manu Caddie
With the launch of New Zealand's medical cannabis program two months away and a referendum to legalize adult-use marijuana slated for later this year, businesses from around the world already have their sights set on the Oceanic market. New Zealand's Medicinal...
Deadline nears for proposals to renovate new Quebec cannabis stores
Prospective contractors in Quebec have until Feb. 3 to submit proposals to renovate almost five dozen new adult-use cannabis branches slated to be opened over the coming three years.
BC’s adult-use cannabis sales spike in November to pace Canadian growth
British Columbia accounted for almost all of Canada’s latest month-over-month increase in adult-use marijuana sales as the nation’s westernmost province is seeing improved access with a slate of new store openings.
Aphria secures CA$100 million injection from anonymous investor
Canadian cannabis producer Aphria said Friday it has entered into an agreement with an institutional investor for a strategic investment worth 100 million Canadian dollars ($76 million). Chief Corporate Affairs Officer Tamara Macgregor told Marijuana Business Daily...
